The Use of Immunotherapy in Chronic Lymphocytic Leukemia
DOI:
https://doi.org/10.58445/rars.1179Keywords:
Chronic lymphocytic leukemia, Immunotherapy, CancerAbstract
The most prevalent form of hematologic cancer in the Western hemisphere, chronic lymphocytic leukemia (CLL) affects millions every year. CLL has various methods of treatment however is known to be difficult to treat as it runs in the bloodstream and cannot be surgically removed. Aside from methods such as chemotherapy, immunotherapy is an emerging treatment that displays positive results. Options of immunotherapy for CLL include monoclonal antibodies such as ibrutinib or adoptive cell therapies such as CAR T cell therapy. Although immunotherapy demonstrates promising outcomes, CLL's ability to develop resistance becomes a major limitation. For this reason, it is necessary to investigate immunotherapy further to make advancements in treatment for CLL patients.
References
Hallek M. (2019). Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. American journal of hematology, 94(11), 1266–1287. https://doi.org/10.1002/ajh.25595
Kipps, T. J., Stevenson, F. K., Wu, C. J., Croce, C. M., Packham, G., Wierda, W. G., O'Brien, S., Gribben, J., & Rai, K. (2017). Chronic lymphocytic leukemia. Nature reviews. Disease primers, 3, 16096. https://doi.org/10.1038/nrdp.2016.96
Balducci, L., & Dolan, D. (2015). Chronic Lymphocytic Leukemia in the Elderly: Epidemiology and Proposed Patient-Related Approach. Cancer control : journal of the Moffitt Cancer Center, 22(4 Suppl), 3–6. https://doi.org/10.1177/107327481502204s02
Hallek, M., & Al-Sawaf, O. (2021). Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. American journal of hematology, 96(12), 1679–1705. https://doi.org/10.1002/ajh.26367
Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., Wan, Y., Zhang, W., Shukla, S. A., Vartanov, A., Fernandes, S. M., Saksena, G., Cibulskis, K., Tesar, B., Gabriel, S., Hacohen, N., … Wu, C. J. (2013). Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell, 152(4), 714–726. https://doi.org/10.1016/j.cell.2013.01.019
Freeman, C. L., & Gribben, J. G. (2016). Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). Current hematologic malignancy reports, 11(1), 29–36. https://doi.org/10.1007/s11899-015-0295-9
Roselle, C., Horikawa, I., Chen, L., Kelly, A. R., Gonzales, D., Da, T., Wellhausen, N., Rommel, P. C., Baker, D., Suhoski, M., Scholler, J., O'Connor, R. S., Young, R. M., Harris, C. C., & June, C. H. (2024). Enhancing chimeric antigen receptor T cell therapy by modulating the p53 signaling network with Δ133p53α. Proceedings of the National Academy of Sciences of the United States of America, 121(10), e2317735121. https://doi.org/10.1073/pnas.2317735121
Mhibik, M., Wiestner, A., & Sun, C. (2019). Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL. International journal of molecular sciences, 21(1), 68. https://doi.org/10.3390/ijms21010068
Roessner, P. M., & Seiffert, M. (2020). T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?. Leukemia, 34(8), 2012–2024. https://doi.org/10.1038/s41375-020-0873-2
NCT03204188
NCT06364423
Additional Files
Posted
Categories
License
Copyright (c) 2024 Shreya Sarangmath
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.